Ambrx Biopharma Inc.
Ambrx Biopharma Inc. (AMAM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
amam · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Ambrx Biopharma Inc. (AMAM) measures how much investors pay for each dollar of the company's trailing earnings. AMAM's current PE ratio of N/A is calculated by dividing its stock price of $28.00 by its TTM earnings per share of -$2.02.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2019 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Ambrx Biopharma Inc.You AMAM | $1.8B | N/A | — | -$2.02 |
 Biotest AG BIESF | $1.6B | 41.48x | +75.9% | $0.71 |
 BELLUS Health Inc. BLU | $1.9B | N/A | — | -$0.66 |
 DICE Therapeutics, Inc. DICE | $2.3B | N/A | — | -$2.07 |
 EQRx, Inc. EQRX | $1.1B | 5.68x | -75.9% | $0.43 |
 Fusion Pharmaceuticals Inc. FUSN | $1.8B | N/A | — | -$1.45 |
 Kadmon Holdings, Inc. KDMN | $0M | N/A | — | -$0.66 |
Industry Average 2 peers with valid PE | — | 23.58x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-2.02 | — | |
2021-12-31 FY2021 | — | $-3.34 | — | |
2020-12-31 FY2020 | — | $-0.47 | — | |
2019-12-31 FY2019 | — | $-0.59 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Ambrx Biopharma Inc. (AMAM) measures how much investors pay for each dollar of the company's trailing earnings. AMAM's current PE ratio of N/A is calculated by dividing its stock price of $28.00 by its TTM earnings per share of -$2.02.
Frequently asked questions
AMAM pe ratio · 6 questionsAMAM's current PE ratio is N/A as of 2026-06-09, based on a stock price of $28.00 and TTM EPS of -$2.02. Data sourced from Financial Modeling Prep via AMAM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Ambrx Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09